RedHill Biopharma adds Mexico and Brazil to Phase 2/3 clinical study evaluating opaganib in patients hospitalized with severe SARS-CoV-2 infection and pneumonia
Wednesday, July 22, 2020
=RedHill Biopharma (RDHL) Accelerates Phase 2/3 COVID-19 Program with Addition of Brazil and Mexico
RedHill Biopharma adds Mexico and Brazil to Phase 2/3 clinical study evaluating opaganib in patients hospitalized with severe SARS-CoV-2 infection and pneumonia
Labels:
coronavirus,
RDHL
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment